Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

   Active, not recruiting · Phase 1 · Advanced Solid Tumor

   NCT06244485 · Daiichi Sankyo Inc. · 17 U.S. investigators

   $2.8Mresearch payments

2. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

   Active, not recruiting · Phase 1, Phase 2 · Multiple Myeloma

   NCT05828511 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

   $2.7Mresearch payments

3. A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

   Completed · Phase 1 · Alzheimer Disease

   NCT04451408 · Eli Lilly and Company · 3 U.S. investigators

   $2.7Mresearch payments

4. Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

   Completed · Phase 1 · Schizophrenia or Schizoaffective

   NCT06627413 · Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) · 2 U.S. investigators

   $2.7Mresearch payments

5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   Recruiting · Phase 1 · Metastatic Solid Tumor

   NCT06465069 · Eli Lilly and Company · 15 U.S. investigators

   $2.7Mresearch payments

6. Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

   Active, not recruiting · Phase 1 · Breast Cancer

   NCT05633979 · Daiichi Sankyo Inc. · 1 U.S. investigator

   $2.7Mresearch payments

7. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

   Recruiting · Phase 1, Phase 2 · Multiple Myeloma

   NCT03761108 · Regeneron Pharmaceuticals, Inc. · 16 U.S. investigators

   $2.7Mresearch payments

8. Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

   Active, not recruiting · Phase 3 · Pneumococcal Immunization

   NCT06736041 · Sanofi Pasteur Inc. · 53 U.S. investigators

   $2.7Mresearch payments

9. A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

   Active, not recruiting · Phase 1, Phase 2 · Non-Small Cell Lung Cancer

   NCT03157128 · Eli Lilly and Company · 28 U.S. investigators

   $2.6Mresearch payments

10. Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

    Completed · Phase 1, Phase 2 · Respiratory Syncytial Virus Infection

    NCT06134648 · Sanofi US Services Inc. · 13 U.S. investigators

    $2.6Mresearch payments

11. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

    Completed · Phase 3 · Schizophrenia

    NCT04820309 · E.r. Squibb & Sons, L.l.c. · 43 U.S. investigators

    $2.6Mresearch payments

12. Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

    Active, not recruiting · Phase 3 · Type 2 Diabetes

    NCT06297603 · Eli Lilly and Company · 37 U.S. investigators

    $2.6Mresearch payments

13. A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

    Active, not recruiting · Phase 2 · Lymphoma, Non-Hodgkin

    NCT04245839 · Celgene Corporation · 19 U.S. investigators

    $2.6Mresearch payments

14. A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteers

    NCT06571266 · AbbVie Inc. · 2 U.S. investigators

    $2.6Mresearch payments

15. Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

    Active, not recruiting · Phase 3 · Pneumococcal Immunization

    NCT06824194 · Sanofi Pasteur Inc. · 63 U.S. investigators

    $2.6Mresearch payments

16. A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

    Active, not recruiting · Phase 3 · Relapsing Multiple Sclerosis

    NCT06372145 · Genzyme Corporation · 49 U.S. investigators

    $2.6Mresearch payments

17. A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

    Completed · Phase 3 · Dermatitis Atopic

    NCT06224348 · Sanofi US Services Inc. · 41 U.S. investigators

    $2.6Mresearch payments

18. A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

    Recruiting · Phase 1 · Alzheimer Disease

    NCT06657768 · Eli Lilly and Company · 6 U.S. investigators

    $2.6Mresearch payments

19. A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

    Recruiting · Phase 1, Phase 2 · Myelofibrosis

    NCT04176198 · Sumitomo Pharma America, Inc. · 29 U.S. investigators

    $2.6Mresearch payments

20. A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

    Completed · Phase 2 · Knee Osteoarthritis

    NCT01925261 · American Regent · 36 U.S. investigators

    $2.5Mresearch payments

21. Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

    Active, not recruiting · Phase 2 · Ann Arbor Stage II Follicular Lymphoma

    NCT04450173 · AbbVie Inc. · 1 U.S. investigator

    $2.5Mresearch payments

22. A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

    Terminated · Phase 1 · Herpes Zoster

    NCT05701800 · ModernaTX, Inc. · 20 U.S. investigators

    $2.5Mresearch payments

23. A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteers

    NCT07146750 · Sanofi US Services Inc. · 1 U.S. investigator

    $2.5Mresearch payments

24. Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

    Terminated · Phase 3 · Traumatic Injury

    NCT05568888 · Csl Behring · 78 U.S. investigators

    $2.5Mresearch payments

25. A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

    Terminated · Phase 2 · Fibrodysplasia Ossificans Progressiva

    NCT05039515 · Ipsen Innovation · 10 U.S. investigators

    $2.5Mresearch payments

26. A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

    Completed · Phase 2 · Schizophrenia

    NCT05227690 · AbbVie Inc. · 20 U.S. investigators

    $2.5Mresearch payments

27. A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

    Active, not recruiting · Phase 2 · Diffuse Large B-Cell Lymphoma

    NCT05451810 · AbbVie Inc. · 69 U.S. investigators

    $2.5Mresearch payments

28. A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

    Active, not recruiting · Phase 3 · Duchenne Muscular Dystrophy

    NCT05881408 · Sarepta Therapeutics, Inc. · 15 U.S. investigators

    $2.4Mresearch payments

29. Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

    Enrolling by invitation · Phase 2 · Asthma

    NCT06609239 · Sanofi US Services Inc. · 27 U.S. investigators

    $2.4Mresearch payments

30. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

    Recruiting · Phase 1, Phase 2 · Extensive Stage-small Cell Lung Cancer

    NCT06362252 · Daiichi Sankyo Inc. · 26 U.S. investigators

    $2.4Mresearch payments

31. OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

    Terminated · Phase 3 · Hyperphagia in Prader-Willi Syndrome

    NCT06420297 · Acadia Pharmaceuticals Inc · 20 U.S. investigators

    $2.4Mresearch payments

32. A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

    Completed · Phase 1, Phase 2 · Genital Herpes

    NCT06033261 · ModernaTX, Inc. · 22 U.S. investigators

    $2.4Mresearch payments

33. Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

    Active, not recruiting · Phase 2 · Mantle Cell Lymphoma

    NCT03282396 · AbbVie Inc. · 1 U.S. investigator

    $2.4Mresearch payments

34. A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

    Completed · Phase 2 · Parkinson Disease

    NCT06055985 · UCB SA · 65 U.S. investigators

    $2.4Mresearch payments

35. A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    Completed · Phase 2 · Overweight or Obesity

    NCT05936151 · Eli Lilly and Company · 22 U.S. investigators

    $2.4Mresearch payments

36. A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

    Completed · Phase 2 · Obesity

    NCT06230523 · Eli Lilly and Company · 47 U.S. investigators

    $2.4Mresearch payments

37. A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

    Recruiting · Phase 3 · Relapsed Refractory Multiple Myeloma (RRMM)

    NCT05730036 · Regeneron Pharmaceuticals, Inc. · 10 U.S. investigators

    $2.3Mresearch payments

38. CHAMPION-AF Clinical Trial

    Active, not recruiting · Not applicable · Atrial Fibrillation

    NCT04394546 · Boston Scientific Corporation · 97 U.S. investigators

    $2.3Mresearch payments

39. Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

    Completed · Phase 3 · Seasonal Influenza

    NCT05827978 · ModernaTX, Inc. · 51 U.S. investigators

    $2.3Mresearch payments

40. Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

    Active, not recruiting · Phase 2 · Autonomous Cortisol Secretion

    NCT06106295 · Esteve Pharmaceuticals LLC · 1 U.S. investigator

    $2.3Mresearch payments

41. A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

    Completed · Phase 2 · Metachromatic Leukodystrophy (MLD)

    NCT03771898 · Takeda Pharmaceuticals U.S.A., Inc. · 9 U.S. investigators

    $2.3Mresearch payments

42. Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

    Completed · Phase 3 · Chronic Obstructive Pulmonary Disease

    NCT04701983 · Sanofi US Services Inc. · 61 U.S. investigators

    $2.3Mresearch payments

43. A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

    Active, not recruiting · Phase 1, Phase 2 · Follicular Lymphoma

    NCT05551936 · Ipsen Biopharmaceuticals, Inc · 4 U.S. investigators

    $2.3Mresearch payments

44. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

    Active, not recruiting · Phase 3 · Vitiligo

    NCT06118411 · AbbVie Inc. · 50 U.S. investigators

    $2.3Mresearch payments

45. A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

    Active, not recruiting · Phase 2 · Melanoma

    NCT06190951 · Regeneron Pharmaceuticals, Inc. · 30 U.S. investigators

    $2.3Mresearch payments

46. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    Recruiting · Phase 3 · Follicular Lymphoma (FL)

    NCT06091254 · Regeneron Pharmaceuticals, Inc. · 20 U.S. investigators

    $2.2Mresearch payments

47. A Study of LY3532226 in Participants With Obesity

    Completed · Phase 1 · Obesity

    NCT06557356 · Eli Lilly and Company · 3 U.S. investigators

    $2.2Mresearch payments

48. X-linked Hypophosphatemia Disease Monitoring Program

    Active, not recruiting · X-linked Hypophosphatemia

    NCT03651505 · Ultragenyx Pharmaceutical Inc. · 23 U.S. investigators

    $2.2Mresearch payments

49. Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

    Completed · Phase 3 · Idiopathic Hypersomnia

    NCT06525077 · Avadel Cns Pharmaceuticals, LLC · 16 U.S. investigators

    $2.2Mresearch payments

50. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Recruiting · Phase 1 · Multiple Myeloma

    NCT05650632 · AbbVie Inc. · 21 U.S. investigators

    $2.2Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.